Moderna, Inc. (NASDAQ:MRNA) Receives $79.50 Average Price Target from Analysts

Shares of Moderna, Inc. (NASDAQ:MRNA) have been given a consensus recommendation of “Hold” by the twenty-two research firms that are presently covering the company, Marketbeat reports. Four analysts have rated the stock with a sell rating, twelve have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $78.83.

MRNA has been the topic of several research reports. Barclays cut their price target on Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. The Goldman Sachs Group lowered their target price on Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research note on Monday, September 16th. Bank of America restated an “underperform” rating and issued a $41.00 price target on shares of Moderna in a report on Tuesday, December 10th. HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price for the company in a research report on Monday, November 18th. Finally, Berenberg Bank started coverage on Moderna in a research note on Tuesday, November 19th. They set a “hold” rating and a $42.00 price objective on the stock.

Insider Transactions at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now directly owns 19,717 shares in the company, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 2,664 shares of company stock worth $115,210 in the last 90 days. 15.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of MRNA. State Street Corp grew its position in shares of Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after buying an additional 1,823,276 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Moderna by 21.0% in the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after acquiring an additional 906,114 shares during the period. Two Sigma Advisers LP purchased a new position in Moderna in the third quarter valued at $23,825,000. International Assets Investment Management LLC increased its position in shares of Moderna by 10,687.1% in the third quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock valued at $21,353,000 after buying an additional 316,552 shares in the last quarter. Finally, Douglas Lane & Associates LLC raised its position in Moderna by 62.9% during the fourth quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock worth $32,175,000 after acquiring an additional 298,715 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Stock Performance

Shares of NASDAQ MRNA opened at $35.15 on Tuesday. The firm has a market cap of $13.53 billion, a price-to-earnings ratio of -6.04 and a beta of 1.60. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. Moderna has a 52 week low of $31.94 and a 52 week high of $170.47. The business’s 50-day simple moving average is $42.15 and its 200-day simple moving average is $68.38.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. During the same period in the prior year, the company posted ($1.39) earnings per share. Moderna’s revenue was up 3.8% on a year-over-year basis. As a group, equities research analysts expect that Moderna will post -9.3 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.